Breast Magnetic Resonance Imaging As It Is, in Contrast to How We Wish It to Be
A partir des données de 4 études portant sur 3 169 patientes atteintes d'un cancer du sein (âge médian : 56,2 ans), cette méta-analyse évalue, du point de vue de la survie sans récidive locale et de la survie sans récidive distante à 8 ans, l'intérêt d'un examen par IRM pour stadifier la maladie avant l'opération
There is perhaps no imaging, laboratory, or other study in modern breast care that has become more contentious or emotionally debated than breast magnetic resonance imaging (MRI). The first study on this modality in breast cancer was published 30 years ago. Since that time, breast MRI has had its share of supporters and detractors, and the meta-analysis that accompanies this editorial may unfortunately be either celebrated or reviled invarious circles,depending on one’s stance or hopes for the modality. Irrespective of one’s thoughts about the promise of MRI (or lack thereof), the study’s significance lies in the fact that now, more than ever, today’s cost-conscious health care world dictates that we must demonstrate improved outcomes (or some other substantial benefit) to justify costs...
Journal of Clinical Oncology , éditorial en libre accès, 2014